We report a patient with Burkitt's lymphoma involving the liver and retroperitoneal lymph nodes who developed acute, progressive, quadriplegia associated with sphincter dysfunctions and an ascending sensory level after the 2 nd dose of intrathecal methotrexate. The motor deficits and the spinal dysfunction persisted in spite of discontinuation of the methotrexate, as well as treatments with intrathecal steroids, pulse intravenous steroids, and intravenous immunoglobulin. The status of the lymphoma was improving on systemic chemotherapy. Whether the progressive motor neuropathy and progressive myelopathy are a toxicity of intrathecal methotrexate or a paraneoplastic phenomenon is a matter of debate.
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Introduction:
Neurological complications of lymphoma are not rare. Usually they are secondary to involvement of the brain with the disease, or infiltration of the meninges or nerve roots with lymphomatous cells. Peripheral nervous system pathology can occur as a direct effect of the systemic or intrathecal chemotherapy. Nevertheless, there are several reports of disease of the central and peripheral nervous systems in association with lymphoma either as a paraneoplastic syndrome or idiosyncratic effect of the intrathecal treatment (1). We present a case of progressive myelopathy and motor polyneuropathy associated with lymphoma and following intrathecal chemotherapy who deteriorated in spite of tumor regression and interruption of treatment.
3
Case Report:
We report the case of a 45 year old man, known case of p-ANCA vasculitis with secondary end stage renal failure who underwent renal transplantation and was maintained on immunosuppressants. No systemic of CSF evidence for an underlying infectious process could be confirmed.
Three weeks later the patient developed atrophy and weakness up to the shoulder girdle muscles and a rise in the sensory level up to D3 T3. MRI revealed expansion of the cord with diffuse T2 high signal intensity involving the grey matter most prominent in the cervical region. There was a small focus of bleed within the cord at T12 level and diffuse enhancement after contrast administration along the anterior aspect of the thoracic cord. (Fig 1) . CSF showed 256 WBC all The patient eventually died few weeks later secondary to respiratory failure and cardia arrest. No autopsy was performed.
Discussion:
The interesting findings in the case we are presenting is the fact that the patient developed subacute, progressive, myelopathy and demyelinating motor polyneuropathy at the same time.
The difficulty is in the diagnosis of whether this severe progressive central and peripheral nervous system dysfunction is secondary to infiltrative lymphoma, versus intrathecal methotrexate toxicity, versus or a paraneoplastic phenomenon.
Intrathecal methotrexate is a treatment which has been reported to produce myelopathy and rarely radiculopathy. The myelopathy occurs in less than 3 % of patients treated with intrathecal Posterior column and lateral cord functions were disturbed as evidenced by sensory and motor evoked studies. CSF studies repeatedly revealed normal WBC count, slightly elevated protein level and no malignant cells. All studied onconeural antibodies were absent and the patient worsened in spite of improvement of his lymphoma.
Considering the above the pathology of the nervous system can not be exclusively attributed neither to a paramalignant phenomenon nor to be secondary to the toxicity of methotrexate which has been discontinued early in the course of the illness. The patient's symptoms progressed in spite of high dose steroid treatment which is described to be the therapy for such toxicity. Furthermore, no cancer cells where detected in the CSF to consider this to be directly the effect of the lymphoma invading the nervous system and the patient progressed in-spite of the regression of his cancer.
Nevertheless, the 2 cases reported by Perez et all 1979 of progressive myelopathy and radiculopathy in association with lymphoma are similar to our case, but had not received any systemic or intrathecal chemotherapy, suggesting that this rare combined progressive 8 myelopathy and motor demyelinating radiculopathy can be a paraneoplastic syndrome associated with lymphoma even if the patient had received intrathecal methotrexate.
Perez et al 1979 (14) report 2 cases of progressive myelopathy and radiculopathy in patients with untreated lymphoma. Thus, progressive myelopathy and demyelinating radiculopathy are diseases that are associated with lymphoma and its treatment either as a direct effect of the treatment or a paraneoplastic association with the cancer. 
